Related Organization(s)

You just read:

Ipsen and Servier announce initial Phase 1/2 clinical data evaluating liposomal irinotecan (ONIVYDE®) as an investigational first-line treatment for metastatic pancreatic cancer at ESMO 21st World Congress on Gastrointestinal Cancer

News provided by

Servier Canada Inc.

Jul 05, 2019, 15:26 ET